title: Prolonged systemic delivery of peptide drugs by long-circulating liposomes: illustration with vasopressin in the Brattleboro rat.
abstract: The value of novel systemically long-circulating liposomes to prolong the duration of an antidiuretic hormone, arg8-vasopressin (VP), was investigated as a representative of low molecular weight peptides with rapid clearance. Cholesterol content was found to have a controlling effect on VP release in serum. Three types of liposomes were selected for urine production measurements in VP deficient Brattleboro rats. One contained phosphatidylserine (PS), which was rapidly cleared from the circulation. In the other two liposomes, the PS component was replaced by either phosphatidylglycerol or a novel phospholipid derivatized with polyethylene glycol (PEG); both showing prolonged circulation. Free VP (up to 8 micrograms/kg) gave reduced urine production for less than 24 hr. The PG formulation exhibited a dose-dependent prolonged duration of bioactivity of up to 4 days. Substitution of PEG-PE resulted in a 2-day delay followed by a prolonged duration of bioactivity for over 4 days. The duration of the prolonged bioactivity was not dose dependent but the amplitude was. This is attributed to VP release from liposomes which have distributed intact to another compartment without having been taken up by the RES. By balancing liposome circulation time, release rate, and dose, long-circulating liposomes can be applied to prolong the biological activity of a therapeutic peptide.
authors.affiliation: Liposome Technology Inc., Menlo Park, California 94025.
authors.forename: M C
authors.initials: MC
authors.lastname: Woodle
authors.forename: G
authors.initials: G
authors.lastname: Storm
authors.forename: M S
authors.initials: MS
authors.lastname: Newman
authors.forename: J J
authors.initials: JJ
authors.lastname: Jekot
authors.forename: L R
authors.initials: LR
authors.lastname: Collins
authors.forename: F J
authors.initials: FJ
authors.lastname: Martin
authors.forename: F C
authors.initials: FC
authors.lastname: Szoka
mesh_terms: D000818:Animals; D001127:Arginine Vasopressin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000652:urine; D003692:Delayed-Action Preparations; D004231:Diuresis / Q000187:drug effects; D004337:Drug Carriers; D007275:Injections, Intravenous; D008081:Liposomes; D008297:Male; D010455:Peptides / Q000008:administration & dosage*; D010715:Phosphatidylglycerols / Q000737:chemistry; D010718:Phosphatidylserines / Q000737:chemistry; D051381:Rats; D011910:Rats, Brattleboro; D014563:Urodynamics / Q000187:drug effects
chemical_list: D003692:Delayed-Action Preparations; D004337:Drug Carriers; D008081:Liposomes; D010455:Peptides; D010715:Phosphatidylglycerols; D010718:Phosphatidylserines; D001127:Arginine Vasopressin